What question did this study set out to answer?

To assess how the timing of subcutaneous exenatide administration relative to a standardized meal affects postprandial glucose and insulin pharmacodynamics in patients with type 2 diabetes.

January 16, 2006Diabetic Medicine

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

View Full Paper

Ask AI

Bookmark

To assess how the timing of subcutaneous exenatide administration relative to a standardized meal affects postprandial glucose and insulin pharmacodynamics in patients with type 2 diabetes.
Conducted a single-centre, open-label, placebo-controlled, randomized, six-way crossover study in 18 patients with type 2 diabetes.
Participants received subcutaneous injections of placebo (-15 min) or 10 µg exenatide at -60, -15, 0, +30, or +60 min relative to a standardized breakfast on six consecutive days, with serial blood sampling for glucose and insulin.
All exenatide injection times significantly lowered incremental postprandial glucose AUC(0-6 h) compared with placebo, with administration at -60, -15, and 0 min significantly reducing peak postprandial glucose (P < 0.0001 for all).
Post-meal dosing resulted in smaller reductions in peak glucose (+30 min, P < 0.05; +60 min, P = 0.21) and occasional transient hypoglycemia.
Pre-meal exenatide dosing significantly reduced peak plasma insulin compared with placebo (P < 0.05 for all pre-meal groups), while the most common adverse events were mild-to-moderate headache, nausea, dyspepsia, and vomiting.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized crossover trial finds optimal postprandial glucose reduction with pre-meal exenatide in type 2 diabetes, supporting flexible dosing up to 60 minutes prior.

Cite This Study

Linnebjerg et al. (2006) studied this question.

synapsesocial.com/papers/6a6fcfd226a7f98052dc67d0 https://doi.org/10.1111/j.1464-5491.2006.01800.x

View Full Paper

Ask AI

Bookmark

Implication

Randomized crossover trial finds optimal postprandial glucose reduction with pre-meal exenatide in type 2 diabetes, supporting flexible dosing up to 60 minutes prior.

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

Key Points

Discussion

Implication

Cite This Study

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider